DDX23 and pancreatic ductal adenocarcinoma: In addition, METTL3 improves the progression of pancreatic ductal adenocarcinoma and resistance to gemcitabine by modifying m6A of DDX23 mRNA [88]. Based on the literature above, we can see that m6A is very promising for enhancing drug resistance.